Skip to main content

Table 1 Association of DOT1L expression with the clinicopathological features of patients with borderline and malignant ovarian tumors

From: Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer

Characteristics Sample DOT1L expression χ 2 P
   Low expression High expression   
Age at diagnosis 235    0.120 0.729
 ≤50 114 51 (44.7%) 63 (55.3%)   
 >50 117 55 (47.0%) 62 (53.0%)   
 Unknown 4     
FIGO stage 235    17.655 0.001
 I 20 18 (90.0%) 2 (10.0%)   
 II 17 8 (47.1%) 9 (52.9%)   
 III 159 66 (41.5%) 93 (58.5%)   
 IV 29 11 (37.9%) 18 (62.1%)   
 Unknown 10     
Histologic grade 235    8.831 0.012
 Grade 1 40 27 (67.5%) 13 (32.5%)   
 Grade 2 58 24 (41.4%) 34 (58.6%)   
 Grade 3 120 50 (41.7%) 70 (58.3%)   
 Unknown 17     
Ascites 235    0.005 0.944
 Yes 173 78 (45.1%) 95 (54.9%)   
 No 36 16 (44.4%) 20 (55.6%)   
 Unknown 26     
LN metastasis 235    4.392 0.036
 Yes 73 29 (39.7%) 44 (60.3%)   
 No 106 59 (55.7%) 47 (44.3%)   
 Unknown 56     
Preoperative CA125 (U/ml) 235    1.829 0.176
 ≤600 68 33 (48.5%) 35 (51.5%)   
 >600 80 30 (37.5%) 50 (62.5%)   
 Unknown 87